Dianthus Therapeutics (DNTH) Competitors

Dianthus Therapeutics logo
$89.55 -2.26 (-2.46%)
Closing price 04:00 PM Eastern
Extended Trading
$89.20 -0.35 (-0.39%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DNTH vs. EXEL, ASND, BBIO, SMMT, and KYMR

Should you buy Dianthus Therapeutics stock or one of its competitors? Dianthus Therapeutics's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dianthus Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Exelixis has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exelixis$2.50B6.74$782.57M$3.3420.66
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A

Exelixis has a net margin of 35.45% compared to Dianthus Therapeutics' net margin of -7,436.50%. Exelixis' return on equity of 45.54% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Exelixis35.45% 45.54% 33.90%
Dianthus Therapeutics -7,436.50%-19.68%-18.95%

Exelixis currently has a consensus price target of $58.62, indicating a potential downside of 15.05%. Dianthus Therapeutics has a consensus price target of $128.77, indicating a potential upside of 40.26%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis
1 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.39
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

Exelixis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

In the previous week, Dianthus Therapeutics had 15 more articles in the media than Exelixis. MarketBeat recorded 28 mentions for Dianthus Therapeutics and 13 mentions for Exelixis. Dianthus Therapeutics' average media sentiment score of 0.61 beat Exelixis' score of 0.46 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exelixis
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dianthus Therapeutics beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 29 mentions for Ascendis Pharma A/S and 28 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Dianthus Therapeutics' score of 0.61 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00

Dianthus Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Dianthus Therapeutics currently has a consensus price target of $128.77, indicating a potential upside of 40.26%. Ascendis Pharma A/S has a consensus price target of $313.52, indicating a potential upside of 13.85%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90

Ascendis Pharma A/S has a net margin of 73.26% compared to Dianthus Therapeutics' net margin of -7,436.50%. Ascendis Pharma A/S's return on equity of 32.47% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-7,436.50% -19.68% -18.95%
Ascendis Pharma A/S 73.26%32.47%13.26%

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

BridgeBio Pharma currently has a consensus target price of $104.42, suggesting a potential upside of 33.36%. Dianthus Therapeutics has a consensus target price of $128.77, suggesting a potential upside of 40.26%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Dianthus Therapeutics had 16 more articles in the media than BridgeBio Pharma. MarketBeat recorded 28 mentions for Dianthus Therapeutics and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Dianthus Therapeutics' score of 0.61 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Dianthus Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A

BridgeBio Pharma has a net margin of -59.84% compared to Dianthus Therapeutics' net margin of -7,436.50%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-59.84% N/A -39.81%
Dianthus Therapeutics -7,436.50%-19.68%-18.95%

Summary

Dianthus Therapeutics beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Dianthus Therapeutics had 21 more articles in the media than Summit Therapeutics. MarketBeat recorded 28 mentions for Dianthus Therapeutics and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Dianthus Therapeutics' score of 0.61 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 81.8% of Summit Therapeutics shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher revenue and earnings than Summit Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A

Summit Therapeutics has a beta of -1.49, meaning that its share price is 249% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Summit Therapeutics presently has a consensus price target of $28.61, suggesting a potential upside of 102.17%. Dianthus Therapeutics has a consensus price target of $128.77, suggesting a potential upside of 40.26%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summit Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,436.50%. Dianthus Therapeutics' return on equity of -19.68% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -138.82% -117.11%
Dianthus Therapeutics -7,436.50%-19.68%-18.95%

Summary

Dianthus Therapeutics beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Kymera Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Dianthus Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,534.23-$162.34M-$3.99N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

In the previous week, Dianthus Therapeutics had 24 more articles in the media than Kymera Therapeutics. MarketBeat recorded 28 mentions for Dianthus Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Dianthus Therapeutics' score of 0.61 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dianthus Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dianthus Therapeutics presently has a consensus price target of $128.77, suggesting a potential upside of 40.26%. Kymera Therapeutics has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Dianthus Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

Dianthus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Dianthus Therapeutics' net margin of -7,436.50%. Dianthus Therapeutics' return on equity of -19.68% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-7,436.50% -19.68% -18.95%
Kymera Therapeutics -285.33%-22.39%-20.48%

Summary

Dianthus Therapeutics beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNTH vs. The Competition

MetricDianthus TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.21B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-22.4426.5532.9127.37
Price / Sales2,471.8416.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book4.064.074.403.70
Net Income-$162.34M-$22.86M$3.52B$392.17M
7 Day Performance-0.50%-7.26%-5.34%-4.53%
1 Month Performance24.22%-4.96%-3.61%-5.86%
1 Year Performance119.22%-2.87%0.01%-7.78%

Dianthus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNTH
Dianthus Therapeutics
2.2704 of 5 stars
$89.55
-2.5%
$128.77
+43.8%
+124.7%$5.21B$2.04MN/A92
EXEL
Exelixis
2.2728 of 5 stars
$70.58
-1.6%
$58.85
-16.6%
+65.7%$17.51B$2.32B21.131,077
ASND
Ascendis Pharma A/S
4.2447 of 5 stars
$256.55
-1.3%
$305.95
+19.3%
+34.7%$16.21B$1.05B19.901,189
BBIO
BridgeBio Pharma
3.5932 of 5 stars
$78.67
+0.9%
$104.26
+32.5%
+17.9%$15.18B$502.08MN/A839
SMMT
Summit Therapeutics
2.6441 of 5 stars
$17.83
-0.1%
$28.61
+60.4%
-21.5%$14.27BN/AN/A265

Related Companies and Tools


This page (NASDAQ:DNTH) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners